Valbiotis SA (ALVAL) Price & Analysis

Compare

5 Followers

ALVAL Stock Chart & Stats

€0.72

€0.05(3.27%)

At close: Jan 09 4:00 PM EST

€0.72

€0.05(3.27%)

Day’s Range― - ―

52-Week Range€0.54 - €1.30

Previous CloseN/A

Volume46.53K

Average Volume (3M)112.19K

Market Cap

€23.69M

Enterprise Value€20.07M

Total Cash (Recent Filing)€11.58M

Total Debt (Recent Filing)€5.72M

Price to Earnings (P/E)―

Beta0.82

Next Earnings

Sep 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding23,698,235

10 Day Avg. Volume162,174

30 Day Avg. Volume112,190

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)2.36

Price to Sales (P/S)18.17

P/FCF Ratio-2.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.35

Revenue Forecast (FY)€4.53M

Bulls Say, Bears Say

Bulls Say

Business Model & DifferentiationValbiotis operates in nutraceuticals with clinically-oriented formulations targeting metabolic and cardiovascular prevention. This product-led, science-backed positioning supports durable differentiation versus generic supplements and can enable recurring sales and premium pricing if clinical claims sustain commercial adoption.

Manageable LeverageReported debt-to-equity in the mid range (≈0.35–0.98 historically, ~0.73 in 2025) implies interest and leverage are not extreme. That moderate capital structure gives the company more structural flexibility to secure additional financing or absorb near-term operating losses without immediate solvency pressure, supporting continuity of R&D and commercialization.

Demonstrated Revenue Rebound PotentialThe sharp 2025 revenue rebound demonstrates the company can generate commercial sales after prior troughs, indicating tangible market traction or successful product placements. While volatile, the ability to reaccelerate revenue is a durable positive if management can translate episodic gains into stable, repeatable channels and scale fixed-cost absorption.

Bears Say

Persistent Cash Burn & Negative FCFSustained negative operating and free cash flow means the business cannot self-fund growth or operations long-term. Persistent cash burn forces reliance on external capital, increasing dilution risk and constraining investments. Over multiple quarters this undermines financial resilience and strategic optionality.

Consistent Losses & Negative Gross ProfitDeep, recurring operating and net losses and recent negative gross profit indicate the current cost structure and pricing cannot cover direct costs at scale. This structural margin weakness threatens long-term profitability unless the company materially improves unit economics, lowers costs, or achieves substantially higher, sustainable revenues.

Declining Equity And Asset BaseShrinking equity and falling asset levels reduce the balance sheet buffer and financial flexibility. That trend raises the likelihood of future financing needs on unfavorable terms, increases dilution risk for shareholders, and limits the company's ability to absorb shocks or fund expansion without external support.

Valbiotis SA News

Valbiotis SA’s TOTUM-448 Trial: A Potential Game-Changer for Liver Health

Valbiotis SA (($DE:8JD)) announced an update on their ongoing clinical study. Study Overview: Valbiotis SA is conducting a...

5M ago

8JD

Valbiotis Announces Monthly Voting Rights and Share Capital Update

Valbiotis SA ( ($FR:ALVAL) ) has shared an update. Valbiotis has announced its monthly information on the total...

12M ago

Valbiotis Introduces Lipidrive as a Safe Alternative to Red Yeast Rice

Valbiotis SA ( ($FR:ALVAL) ) has shared an announcement. Valbiotis has introduced Lipidrive, a scientifically proven alternative to...

12M ago

Valbiotis SA Confirms Strategic Growth and Successful Product Launch

Valbiotis SA ( ($FR:ALVAL) ) just unveiled an update. Valbiotis SA has transitioned from an R&D-focused company to...

1y ago

Valbiotis Releases Monthly Voting Rights and Share Capital Data

The latest announcement is out from Valbiotis SA ( ($FR:ALVAL) ). Valbiotis announced its monthly voting rights and...

1y ago

Valbiotis Releases Monthly Voting Rights and Shares Update

An announcement from Valbiotis SA ( ($FR:ALVAL) ) is now available. Valbiotis has disclosed its monthly update on...

1y ago

Valbiotis Launches Innovative Metabolic Health Supplement in France

Valbiotis SA ( ($FR:ALVAL) ) just unveiled an announcement. Valbiotis announced the launch of its dietary supplement, Valbiotis®PRO...

1y ago

Valbiotis Sets Ambitious 2030 Growth Targets with Focus on Natural Health Supplements

Valbiotis SA ( ($FR:ALVAL) ) has shared an announcement. Valbiotis has announced its strategic and financial objectives for...

1y ago

Valbiotis Achieves Clinical Success with Lipidrive® for Cholesterol Management

Valbiotis SA ( ($FR:ALVAL) ) has issued an update. Valbiotis has announced the successful results of its Phase...

1y ago

Valbiotis Reports Half-Year Liquidity Contract Update

Valbiotis SA ( ($FR:ALVAL) ) just unveiled an announcement. Valbiotis has released its half-year liquidity contract report showing...

1y ago

ALVAL FAQ

What was Valbiotis SA’s price range in the past 12 months?

Valbiotis SA lowest stock price was €0.54 and its highest was €1.30 in the past 12 months.

What is Valbiotis SA’s market cap?

Valbiotis SA’s market cap is €23.69M.

When is Valbiotis SA’s upcoming earnings report date?

Valbiotis SA’s upcoming earnings report date is Sep 24, 2026 which is in 192 days.

How were Valbiotis SA’s earnings last quarter?

Valbiotis SA released its earnings results on Mar 02, 2026. The company reported -€0.204 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.204.

Is Valbiotis SA overvalued?

According to Wall Street analysts Valbiotis SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Valbiotis SA pay dividends?

Valbiotis SA does not currently pay dividends.

What is Valbiotis SA’s EPS estimate?

Valbiotis SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Valbiotis SA have?

Valbiotis SA has 23,698,235 shares outstanding.

What happened to Valbiotis SA’s price movement after its last earnings report?

Valbiotis SA reported an EPS of -€0.204 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.971%.

Which hedge fund is a major shareholder of Valbiotis SA?

Currently, no hedge funds are holding shares in FR:ALVAL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Valbiotis SA

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.